SRR8518156
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.690
- INTERFERON_GAMMA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.600
- E2F_TARGETS+0.520
- IL6_JAK_STAT3_SIGNALING+0.490
- MTORC1_SIGNALING+0.490
- MYC_TARGETS_V1+0.490
- INFLAMMATORY_RESPONSE+0.430
- MYC_TARGETS_V2+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.430
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.400
- HEDGEHOG_SIGNALING-0.400
- MYOGENESIS-0.380
- NOTCH_SIGNALING-0.380
- UV_RESPONSE_DN-0.380
- APICAL_JUNCTION-0.350
- TGF_BETA_SIGNALING-0.340
- ESTROGEN_RESPONSE_EARLY-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.946 |
| 2 | TCGA-C8-A1HM-01A-12R-A137-07 | — | C | 0.932 |
| 3 | SRR1313135 | — | C | 0.912 |
| 4 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.904 |
| 5 | TCGA-A2-A0EQ-01A-11R-A034-07 | — | C | 0.898 |
| 6 | SRR8518291 | — | D | 0.898 |
| 7 | TCGA-E9-A22D-01A-11R-A157-07 | — | D | 0.896 |
| 8 | 9a1be9ca-1641-4eac-beb9-3b54ec277a7c | — | — | 0.887 |
| 9 | C3N-03764 | — | cohortA1 | 0.885 |
| 10 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.690 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |